[{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SAN711","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saniona \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ Acadia Pharmaceuticals"},{"orgOrder":0,"company":"Vesper Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VES001","moa":"PGRN","graph1":"Neurology","graph2":"Phase I","graph3":"Vesper Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vesper Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vesper Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vesper Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VES001","moa":"PGRN","graph1":"Neurology","graph2":"Phase I","graph3":"Vesper Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vesper Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vesper Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vesper Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VES001","moa":"PGRN","graph1":"Neurology","graph2":"Phase I","graph3":"Vesper Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vesper Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vesper Bio \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"SAN711","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Saniona \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAN711","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAN711","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NMD1343","moa":"CIC-1","graph1":"Neurology","graph2":"Phase I","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IRX4204","moa":"RXR nuclear receptor","graph1":"Neurology","graph2":"Phase I","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IO Biotech \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Under the license agreement, Acadia will acquire exclusive rights to further the clinical development of SAN711, which is being studied as a treatment for Essential Tremors.

                          Product Name : SAN711

                          Product Type : Other Small Molecule

                          Upfront Cash : $28.0 million

                          November 26, 2024

                          Lead Product(s) : SAN711

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Acadia Pharmaceuticals

                          Deal Size : $610.0 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : IRX4204 is a highly potent and highly selective, orally available, third generation RXR agonist compound which IS being tested in early phase clinical trials in patients with Parkinson’s disease

                          Product Name : IRX4204

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 07, 2024

                          Lead Product(s) : IRX4204

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Liraglutide-Generic is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is investigated for the treatment of patients with mild alzheimer's disease.

                          Product Name : Victoza

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          July 29, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : VES001, a oral small molecule sortilin receptor inhibitor, is presently completed Phase I evaluation for the treatment of Frontotemporal Dementia.

                          Product Name : VES001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 30, 2024

                          Lead Product(s) : VES001

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : VES001 is a first-in-class oral, brain-penetrant, small molecule sortilin receptor inhibitor, is presently undergoing evaluation for the treatment of Frontotemporal Dementia.

                          Product Name : VES001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 09, 2024

                          Lead Product(s) : VES001

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : VES001, a small molecule sortilin receptor inhibitor, is presently undergoing evaluation in ongoing Phase I clinical trials for the treatment of Frontotemporal Dementia.

                          Product Name : VES001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 12, 2023

                          Lead Product(s) : VES001

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : NMD1343 is a novel small molecule inhibitor of the muscle-specific chloride ion channel, the ClC-1 ion channel, and NMD Pharma’s second clinical development candidate

                          Product Name : NMD1343

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 23, 2023

                          Lead Product(s) : NMD1343

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Data from the trial demonstrated that SAN711 was safe and well tolerated across all dosing cohorts with a favorable absorption and distribution profile. There were no serious adverse events, and all subjects completed the study.

                          Product Name : SAN711

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 30, 2022

                          Lead Product(s) : SAN711

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : SAN711 is an investigational, potential first-in-class positive allosteric modulator of GABA-A α3 receptors, may have the potential to restore spinal inhibitory tone and prevent abnormal pain signaling to the brain.

                          Product Name : SAN711

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 24, 2022

                          Lead Product(s) : SAN711

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The termination of the GABAa5 program provides Saniona with rights to a portfolio of more than 800 molecules; the company intends to evaluate their applicability in rare diseases.

                          Product Name : SAN711

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 11, 2020

                          Lead Product(s) : SAN711

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Boehringer Ingelheim GmbH

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          blank